homeearnings NewsSyngene Q3 results: Biocon unit cuts FY24 revenue growth guidance

Syngene Q3 results: Biocon unit cuts FY24 revenue growth guidance

Syngene's revenue in the third quarter of this financial year jumped 8.6% on a year-on-year basis to ₹853.5 crore, compared to ₹785.9 crore in Q3FY23.

Profile image

By Ajay Vaishnav  Jan 25, 2024 4:04:28 PM IST (Updated)

Listen to the Article(6 Minutes)
2 Min Read
Syngene Q3 results: Biocon unit cuts FY24 revenue growth guidance
Syngene International posted a net profit of 111.5 crore in the quarter ended December 31, 2023. The net profit rose marginally by 1.6% from 109.7 crore the listed contract research and manufacturing services arm of Biocon had posted in Q3FY23. Sequentially, the net profit dropped from ₹116.5 crore it had posted in the September quarter results.

Syngene's revenue in the third quarter of the current financial year jumped 8.6% on a year-on-year basis to 853.5 crore, compared to 785.9 crore in Q3FY23. On a sequential basis, the revenue dropped from 910.1 crore the pharma R&D firm had posted in the September quarter results.
Syngene's EBITDA came in flat at 231.5 crore in Q3FY24 against 231 crore it had posted a year ago in the same quarter. The Biocon subsidiary's margin dropped to 27% in the December quarter on a YoY basis. Its margin was at 29% in Q3FY23.
Syngene has further cut its FY24 revenue growth guidance to be around double digits from earlier mid-teens it had projected in the September quarter, which was also reduced from its high-teens projections before the Q2 results. The company said that a temporary slowdown in biotech funding in the United States will impact growth in the near term.
Syngene International's stock price, however, traded flat in the red, quoting at 694.

Most Read

Share Market Live

View All
Top GainersTop Losers
CurrencyCommodities
CurrencyPriceChange%Change